PMC:7534795 / 5192-5375 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T69623","span":{"begin":38,"end":51},"obj":"Body_part"}],"attributes":[{"id":"A32432","pred":"fma_id","subj":"T69623","obj":"http://purl.org/sig/ont/fma/fma264829"}],"text":"ypertension (Zhang et al., 2020)\nAnti-interleukin-6 • Tocilizumab (anti-IL-6 receptor), siltuximab (anti-IL-6), and sirukumab (anti-IL-6) are proposed as possible treatments to manage"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T78016","span":{"begin":38,"end":51},"obj":"http://purl.obolibrary.org/obo/PR_000001393"}],"text":"ypertension (Zhang et al., 2020)\nAnti-interleukin-6 • Tocilizumab (anti-IL-6 receptor), siltuximab (anti-IL-6), and sirukumab (anti-IL-6) are proposed as possible treatments to manage"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T40","span":{"begin":72,"end":74},"obj":"Chemical"},{"id":"T42","span":{"begin":105,"end":107},"obj":"Chemical"},{"id":"T44","span":{"begin":132,"end":134},"obj":"Chemical"}],"attributes":[{"id":"A40","pred":"chebi_id","subj":"T40","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A41","pred":"chebi_id","subj":"T40","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A42","pred":"chebi_id","subj":"T42","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A43","pred":"chebi_id","subj":"T42","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"},{"id":"A44","pred":"chebi_id","subj":"T44","obj":"http://purl.obolibrary.org/obo/CHEBI_63895"},{"id":"A45","pred":"chebi_id","subj":"T44","obj":"http://purl.obolibrary.org/obo/CHEBI_74072"}],"text":"ypertension (Zhang et al., 2020)\nAnti-interleukin-6 • Tocilizumab (anti-IL-6 receptor), siltuximab (anti-IL-6), and sirukumab (anti-IL-6) are proposed as possible treatments to manage"}

{"project":"LitCovid-PubTator","denotations":[{"id":"156","span":{"begin":38,"end":51},"obj":"Gene"},{"id":"157","span":{"begin":105,"end":109},"obj":"Gene"},{"id":"158","span":{"begin":132,"end":136},"obj":"Gene"}],"attributes":[{"id":"A156","pred":"tao:has_database_id","subj":"156","obj":"Gene:3569"},{"id":"A157","pred":"tao:has_database_id","subj":"157","obj":"Gene:3569"},{"id":"A158","pred":"tao:has_database_id","subj":"158","obj":"Gene:3569"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"ypertension (Zhang et al., 2020)\nAnti-interleukin-6 • Tocilizumab (anti-IL-6 receptor), siltuximab (anti-IL-6), and sirukumab (anti-IL-6) are proposed as possible treatments to manage"}